260 related articles for article (PubMed ID: 7291931)
1. [Long-term effects of a combination of 25-hydroxycholecalciferol and 1-alpha-hydroxycholecalciferol on osteodystrophy in chronic hemodialysis patients].
Sebert JL; Marie A; Kuntz D; Marie P; Gueris J; Smadja A; Fournier A; Quichaud J
Rev Rhum Mal Osteoartic; 1981; 48(7-9):535-41. PubMed ID: 7291931
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization.
Fournier A; Bordier P; Gueris J; Sebert JL; Marie P; Ferrière C; Bedrossian J; DeLuca HF
Kidney Int; 1979 Feb; 15(2):196-204. PubMed ID: 513484
[No Abstract] [Full Text] [Related]
3. 1alpha-Hydroxycholecalciferol in renal osteodystrophy.
Pierides AM; Ellis HA; Ward MK; Simpson W; Kerr DN
Calcif Tissue Res; 1977 May; 22 Suppl():105-11. PubMed ID: 912511
[No Abstract] [Full Text] [Related]
4. The treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol.
Junor BJ; Catto GR; Macleod M
Calcif Tissue Res; 1977 May; 22 Suppl():112-6. PubMed ID: 912512
[No Abstract] [Full Text] [Related]
5. Osteopenia during long-term haemodialysis: response to vitamin D3 analogues.
Muirhead N; Adami S; Fraser RA; Catto GR; Edward N; O'Riordan JL
Proc Eur Dial Transplant Assoc; 1981; 18():567-72. PubMed ID: 6895786
[No Abstract] [Full Text] [Related]
6. Hypophosphataemia and osteomalacia in haemodialysis patients not taking phosphate binders.
Ahmed KY; Varghese Z; Meinhard EA; Baillod RA; Skinner RK; Wills MR; Moorhead JF
Adv Exp Med Biol; 1977; 81():581-90. PubMed ID: 899942
[No Abstract] [Full Text] [Related]
7. 1,25(OH)2D3 and 25-OHD3 in the treatment of renal osteodystrophy: comparison of combined versus 1,25(OH)2D3 administration alone.
Coen G; Taccone Gallucci M; Bonucci E; Ballanti P; Bianchi AR; Bianchini G; Matteucci MC; Mazzaferro S; Picca S; Taggi F; Cinotti GA; Casciani CU
Miner Electrolyte Metab; 1983; 9(1):19-27. PubMed ID: 6687749
[No Abstract] [Full Text] [Related]
8. Therapeutic effects of 25-hydroxycholecalciferol and sodium etidronate on renal osteodystrophy.
Zucchelli P; Catizone L; Casanova S; Fabbri L; Fusaroli M
Miner Electrolyte Metab; 1982 Feb; 7(2):86-96. PubMed ID: 6820473
[TBL] [Abstract][Full Text] [Related]
9. Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH.
Coen G; Ballanti P; Bonucci E; Calabria S; Costantini S; Ferrannini M; Giustini M; Giordano R; Nicolai G; Manni M; Sardella D; Taggi F
Nephron; 2002 May; 91(1):103-11. PubMed ID: 12021526
[TBL] [Abstract][Full Text] [Related]
10. 1 alpha-hydroxycholecalciferol in hemodialysis renal osteodystrophy. Adverse effects of anticonvulsant therapy.
Pierides AM; Kerr DN; Ellis HA; Peart KM; O'Riordan JL; DeLuca HF
Clin Nephrol; 1976 Apr; 3(2):189-96. PubMed ID: 819195
[TBL] [Abstract][Full Text] [Related]
11. 1alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in renal bone disease.
Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; De Luca HF
Calcif Tissue Res; 1976 Aug; 21 Suppl():226-35. PubMed ID: 782662
[No Abstract] [Full Text] [Related]
12. 1,25-dihydroxycholecalciferol in patients with chronic renal failure.
Henderson RG; Ledingham JG; Norman AW; Oliver DO; Preston C; Russell RG; Small DG; Smith R; Warner GT; Woods CG
Proc Eur Dial Transplant Assoc; 1973; 10(0):202-9. PubMed ID: 4802654
[No Abstract] [Full Text] [Related]
13. [Long-term treatment of renalosteodystrophy with 1 alpha-hydroxycholecalciferol].
Marco Franco JE; Alarcón Zurita A; Pizá Buñola C; Morey Molina A; Bestard Palmer J; Mairata Bosch S; Dalmau Diana M
Rev Clin Esp; 1982 Jan; 164(1):33-5. PubMed ID: 7071401
[No Abstract] [Full Text] [Related]
14. Evolution of renal osteodystrophy: correlation of bone histomorphometry and serum mineral and immunoreactive parathyroid hormone values before and after treatment with calcium carbonate or 25-hydroxycholecalciferol.
Bordier PJ; Marie PJ; Arnaud CD
Kidney Int Suppl; 1975 Jan; (2):102-12. PubMed ID: 1057669
[No Abstract] [Full Text] [Related]
15. The pathogenesis of renal osteodystrophy: role of vitamin D, aluminium, parathyroid hormone, calcium and phosphorus.
Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Johnson JR; George CR; Collett P; Kalowski S
Q J Med; 1985 May; 55(217):127-44. PubMed ID: 4001311
[TBL] [Abstract][Full Text] [Related]
16. [Immunoreactive parathyroid hormone, 25-hydroxycalciferol and bone histology in renal osteodystrophy (author's transl)].
Offermann G; Schaefer K; Schulz A; Delling G
Klin Wochenschr; 1976 Jul; 54(13):625-32. PubMed ID: 940299
[TBL] [Abstract][Full Text] [Related]
17. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
Massry SG; Goldstein DA; Malluche HH
Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
[No Abstract] [Full Text] [Related]
18. Treatment of renal osteodystrophy with 1alpha-hydroxycholecalciferol (1alpha-OH-D3) in conjunction with a high dialysate calcium.
Winney RJ; Bone JM; Anderson TJ; Robson JS
Calcif Tissue Res; 1977 May; 22 Suppl():94-100. PubMed ID: 912593
[No Abstract] [Full Text] [Related]
19. 1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease.
Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; de Luca HF
Proc Eur Dial Transplant Assoc; 1976; 12():227-36. PubMed ID: 935115
[TBL] [Abstract][Full Text] [Related]
20. Calcifediol in chronic renal insufficiency. Skeletal response.
Teitelbaum SL; Bone JM; Stein PM; Gilden JJ; Bates M; Boisseau VC; Avioli LV
JAMA; 1976 Jan; 235(2):164-7. PubMed ID: 946022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
